OSCR
Oscar Health, Inc.
OSCR has the edge over TARS overall, supported by stronger fundamentals and stronger modeled upside.
TARS
Tarsus Pharmaceuticals, Inc.
TARS has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
TARS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Healthy | |
| Unavailable |
TARS's revenue and cash flow are currently healthy, but its profitability is weak. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
TARS PE Valuation
TARS has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
TARS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect TARS's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over TARS on earnings quality, reporting a profit while its opponent remains loss making.
TARS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$15.16 | -$13.17 |
| Q2 2026 | -$1.06 | +$1.24 |
| Q1 2026 | -$1.11 | +$1.59 |
| Q4 2025 | -$1.59 | +$1.48 |
| Q3 2025 | -$1.99 | +$1.80 |
| Q2 2025 | -$2.30 | +$2.16 |
| Q1 2025 | -$2.70 | +$2.05 |
| Q4 2024 | -$3.07 | +$1.55 |
TARS lost $15.16 per share over the past year, a bigger loss than the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over TARS on profitability, with a higher operating margin.
TARS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $194.6M | +64% |
| Q2 2026 | $173.9M | +69% |
| Q1 2026 | $162.1M | +107% |
| Q4 2025 | $151.7M | +128% |
| Q3 2025 | $118.7M | +147% |
| Q2 2025 | $102.7M | +152% |
| Q1 2025 | $78.3M | +184% |
| Q4 2024 | $66.4M | +408% |
TARS has the edge over OSCR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -340% | -328 points |
| Q2 2026 | -11% | +10 points |
| Q1 2026 | -3.8% | +30 points |
| Q4 2025 | -5.3% | +32 points |
| Q3 2025 | -12% | +40 points |
| Q2 2025 | -22% | +60 points |
| Q1 2025 | -34% | +103 points |
| Q4 2024 | -37% | +303 points |
TARS's operating margin was −340% last quarter, down 328 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over TARS on cash flow, with more consistent year-over-year improvement.
TARS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.2M | -144% |
| Q2 2026 | $57.2M | +$87.5M |
| Q1 2026 | -$30.5M | -$9.2M |
| Q4 2025 | $13M | +$35.2M |
| Q3 2025 | $16.3M | +$25.3M |
| Q2 2025 | -$30.4M | -$14.9M |
| Q1 2025 | -$21.2M | +$16.7M |
| Q4 2024 | -$22.3M | +$17.1M |
TARS's free cash flow has turned positive after six years mostly in the red: $32M over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
TARS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7% | +3M shares |
| 1 year | +9% | +3.8M shares |
| 3 years | +52% | +15.8M shares |
| 5 years | +125% | +25.8M shares |
| Available history | +326% | +35.5M shares |
TARS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2020 | $1,000 |
| Q1 2020 | $27,000 |
| Q4 2019 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
TARS Net Leverage
TARS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
TARS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.0 | Neutral |
| Stochastic | 44.3 | Neutral |
TARS's weekly RSI is 56 (neutral) and its Stochastic is 44 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TARS PE vs Healthcare Sector
TARS has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
TARS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.3 | 6.3% above |
| 20 week MA | $70.3 | 9.4% above |
| 50 week MA | $69.2 | 11% above |
| 100 week MA | $60.9 | 26% above |
| 200 week MA | $42.9 | 79% above |
TARS is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over TARS on returns for 2026, with the stronger performance.
TARS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.6 | $44.0 | +114% |
| 2021 | $44.0 | $25.9 | -41% |
| 2022 | $25.9 | $14.5 | -44% |
| 2023 | $14.5 | $20.3 | +40% |
| 2024 | $20.3 | $55.0 | +172% |
| 2025 | $55.0 | $81.8 | +49% |
| 2026 YTD | $81.8 | $76.9 | -6% |
TARS's yearly returns have swung widely, from +172% in 2024 to −44% in 2022. It's down 6% so far in 2026.